Tesamorelin is the only one of the two medications with an active FDA approval, whereas sermorelin was withdrawn from commercial marketing in 2009 and is available in the United States only through compounding pharmacies. At Longevity Benchmark, we evaluate peptide therapies against their actual regulatory records and published human trials rather than wellness clinic claims.

The clinical evidence behind these growth hormone-releasing hormone analogues addresses completely different patient populations. Tesamorelin holds an approved indication strictly for reducing excess abdominal fat in human immunodeficiency virus-infected adults with lipodystrophy. Sermorelin holds no current approval for adult use, and clinical trials have never evaluated either medication for fat loss or recovery in healthy adults.

The Verdict

The evidence base confirms substantial deep abdominal fat loss alongside clear monitoring protocols. Neither compound is indicated for cosmetic weight loss, bodybuilding, or anti-aging therapy. Neither medication is approved for healthy adults, and clinical trials confirm that any visceral fat lost on tesamorelin returns rapidly once injections stop.

Sermorelin vs Tesamorelin

DimensionSermorelinTesamorelin
Molecular description 29-amino-acid analogue of growth hormone-releasing hormone 44-amino-acid analogue of human growth hormone-releasing factor, acetate salt, 5135.9 Da molecular weight
Structural modification vs native GHRH Not published Hexenoyl moiety attached to the N-terminal tyrosine of the 44-amino-acid sequence
Current FDA status No approved product on the market. Original approvals withdrawn in June 2009 Approved and commercially marketed as EGRIFTA SV
Approved indication None today. Originally approved for childhood growth hormone deficiency diagnosis and treatment Reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy
Route and frequency Not published Subcutaneous injection once daily into the abdomen at 1.4 mg (0.35 mL reconstituted)
Strongest human evidence Paediatric growth hormone deficiency studies leading to 1997 approval Two 26-week randomized phase 3 trials with 26-week extension phases in HIV lipodystrophy
What the trials measured Not published Visceral adipose tissue by computed tomography scan at L4 to L5, and IGF-1
What no trial has measured Body composition, muscle mass, fat loss, recovery, or sleep in healthy adults Weight loss management, or long-term cardiovascular safety
US supply channel today Compounded preparations Commercial outpatient prescription drug dispensed as brand EGRIFTA SV
Appearance on the FDA significant-safety-risk list Does not appear on the FDA bulk safety list Does not appear on the FDA bulk safety list
Monitoring the label requires No current FDA label or monitoring requirements exist for adults Serum IGF-1 monitoring during therapy

Which One Has an FDA-Approved Product Behind It

Tesamorelin possesses an active prescription drug approval from the FDA, whereas sermorelin does not exist as an approved commercial product anywhere in the United States. The commercial brand for tesamorelin is sold under the trade name EGRIFTA SV. Physicians prescribe it for adult patients who meet its exact labelled indication.

Sermorelin was originally approved in 1997 under the brand name Geref for paediatric diagnostic and therapeutic use. The drug manufacturer, EMD Serono, formally requested the withdrawal of New Drug Applications 19-863 and 20-443 in December 2008 due to commercial considerations. The regulator subsequently issued a complete withdrawal of approval in June 2009.

The Federal Register determination published at 78 FR on March 4, 2013 affirmed that Geref was not withdrawn for reasons of safety or effectiveness. It does not mean compounded sermorelin undergoes the review applied to manufactured pharmaceuticals. Every milligram of sermorelin purchased today comes from compounding pharmacies rather than commercial drug manufacturers.

The Clinical Indications and Prescribing Boundaries

Tesamorelin carries an approved indication strictly for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. That indication was granted in November 2010. The package insert contains clear limitations of use that govern prescribing. Long-term cardiovascular safety remains unestablished, and the drug is explicitly not indicated for weight loss management.

Sermorelin possesses no current approved indication for adults. The relationship between sermorelin and testosterone replacement therapy is evaluated separately.

Neither medication has received regulatory approval for treating age-related changes in body composition. Patients seeking care for hormone optimization should review our guide to sermorelin therapy to understand what clinical oversight requires. When a clinic presents either peptide as a proven intervention for non-HIV abdominal obesity, they are describing uses that the published literature has not confirmed.

Molecular Structure and Half-Life Differences

Sermorelin is a 29-amino-acid analogue of growth hormone-releasing hormone.

Tesamorelin is a 44-amino-acid analogue of human growth hormone-releasing factor. Tesamorelin carries a hexenoyl moiety attached to the N-terminal tyrosine. That modification consists of a C6 chain with a double bond at position 3. The resulting free base equivalent has a molecular weight of 5135.9 Daltons.

Sermorelin clears rapidly from circulation, showing an intravenous plasma half-life of 6 to 7 minutes in product documentation. Other published estimates report an elimination half-life running between 10 and 20 minutes. Tesamorelin is dosed subcutaneously once daily. A detailed exploration of related compounds is available in our analysis of sermorelin vs CJC-1295.

What the Human Trials Actually Measured

Two randomized, double-blind, placebo-controlled phase 3 clinical trials evaluated tesamorelin in HIV-associated lipodystrophy. Each trial enrolled patients across a 26-week main phase followed by an additional 26-week extension phase, utilizing a 2 to 1 randomization design. Investigators evaluated changes in visceral adipose tissue using computed tomography scans at the L4 to L5 vertebral level.

In Study 1, patients receiving tesamorelin achieved an 18 percent decrease in visceral adipose tissue at week 26 compared to a 2 percent increase in the placebo group. That represented a treatment difference of minus 20 percent, with a 95 percent confidence interval from minus 24 to minus 15 percent. The absolute mean reduction reached minus 27 square centimetres compared to plus 4 square centimetres for placebo.

Study 2 demonstrated comparable reductions in deep abdominal fat. Patients on active therapy recorded a 14 percent decrease in visceral fat compared to a 2 percent decrease on placebo, representing a treatment difference of minus 12 percent with a 95 percent confidence interval from minus 16 to minus 7 percent. The absolute change was minus 21 square centimetres versus zero in the control group.

Phase 3 Clinical TrialTreatment Group (n)Relative Visceral Fat Change (Week 26)Absolute Visceral Fat Change (Week 26)
Study 1 (Active) EGRIFTA (n=273) -18% -27 cm²
Study 1 (Control) Placebo (n=137) +2% +4 cm²
Study 2 (Active) EGRIFTA (n=270) -14% -21 cm²
Study 2 (Control) Placebo (n=126) -2% -0 cm²

Discontinuation Effects and the Rebound Phenomenon

The extension phases of the phase 3 trials revealed that visceral fat reductions depend entirely on continuous medication administration. Patients who completed the initial 26 weeks were evaluated through week 52 under alternative regimens. Those who continued active therapy maintained their visceral fat improvements, recording a zero percent change in Study 1 and an additional 5 percent loss in Study 2.

Patients switched from active tesamorelin to placebo experienced rapid visceral fat regain. In Study 1, subjects transitioned to placebo gained back 22 percent visceral fat between weeks 26 and 52. In Study 2, patients re-accumulated 16 percent visceral fat after stopping the drug. The benefits vanished once treatment ceased.

For sermorelin, no comparable discontinuation trials exist in adult populations. Paediatric approvals evaluated growth hormone deficiency rather than adult body composition.

Adverse Reactions and Safety Monitoring

Tesamorelin carries distinct risks documented across its 543 clinical trial participants compared to 263 placebo controls. Injection site reactions occurred in 17 percent of treated patients versus 6 percent on placebo. Arthralgia developed in 13 percent compared to 11 percent. Other reactions included extremity pain at 6 percent versus 5 percent, myalgia at 6 percent versus 2 percent, and peripheral edema at 6 percent versus 2 percent. Hypersensitivity reactions affected 4 percent of participants.

Metabolic changes require active surveillance during tesamorelin therapy. The clinical trials revealed a hazard ratio for new-onset diabetes mellitus of 3.3, with a 95 percent confidence interval from 1.4 to 9.6 compared to placebo. Absolute contraindications include pregnancy, active malignancy, and hypothalamic-pituitary disruption resulting from surgery, trauma, hypophysectomy, or radiation.

Serum insulin-like growth factor 1 concentrations rise substantially on tesamorelin. At week 26, 47 percent of patients exhibited IGF-1 standard deviation scores above plus 2, and 36 percent exceeded plus 3. By week 52, 34 percent remained above plus 2 and 23 percent remained above plus 3. The package insert instructs prescribers to monitor IGF-1 and consider discontinuing treatment on persistent elevation (e.g. above 3 SDS). Sermorelin lacks mandatory monitoring schedules in adults, though testing is discussed in our guide to the IGF-1 test.

Supply Quality and Regulatory Oversight

Prescription sourcing represents a fundamental difference between these two compounds. Tesamorelin is distributed as a commercial outpatient prescription drug under the brand EGRIFTA SV.

Sermorelin is supplied in the United States exclusively through compounding pharmacies. Neither sermorelin nor tesamorelin appears on the official list of bulk substances presenting significant safety risks published by the regulator.

Readers comparing secretagogues should note that alternative compounds face different regulatory restrictions. For example, ipamorelin acetate appears on the FDA category 2 compounding restriction list as of September 29, 2023. Our comparison of sermorelin vs ipamorelin explores those distinctions further. Patients can also review our general analysis of peptide therapy FDA status.

Evaluating Muscle Growth Claims

Neither sermorelin nor tesamorelin has demonstrated anabolic muscle building in clinical trials of healthy adults. Clinical data across both compounds fail to confirm measurable lean mass accumulation in healthy adults.

A meta-analysis by Guo and colleagues in Experimental and Therapeutic Medicine examined testosterone therapy, noting that testosterone increased lean body mass by a mean difference of 1.22 kg. In a prospective, open-label, non-randomised cohort of 12 hypogonadal men with chronic spinal cord injury studied by Bauman and colleagues on testosterone, total body lean tissue mass increased by 2.7 kg at 12 months. Basal energy expenditure remained unchanged at 1753 to 1760 kcal per day in that cohort.

Clinical evidence establishes that tesamorelin is weight neutral. The official package insert attributes a weight-neutral effect. Using either medication with the expectation of significant muscle growth contradicts the published clinical literature.

Frequently Asked Questions

What peptide is better than tesamorelin?

No trial has compared sermorelin and tesamorelin head to head. Tesamorelin is the only one of the two with a live FDA approval and phase 3 trial evidence for reducing excess abdominal fat in HIV-associated lipodystrophy. For healthy individuals seeking general fat loss or muscle hypertrophy, no growth hormone peptide has proven efficacy or safety in randomized controlled trials. Determining which medication is clinically appropriate depends entirely on the underlying medical diagnosis.

Does sermorelin really burn belly fat?

Clinical trials have never evaluated sermorelin for burning belly fat in healthy adults. Sermorelin was studied and approved in 1997 strictly for diagnosing and treating growth hormone deficiency in paediatric patients before its commercial withdrawal in 2009. No published human trial proves that compounded sermorelin reduces visceral or subcutaneous abdominal fat in healthy adults. In contrast, tesamorelin's visceral-fat trials were conducted only in HIV-associated lipodystrophy, and its label states it is not indicated for weight loss management.

Can I stack tesamorelin and sermorelin?

No published clinical trial has tested the combination of tesamorelin and sermorelin.

What is the strongest HGH peptide?

Potency among growth hormone peptides cannot be ranked as a simple continuum because no head-to-head clinical trials compare them directly. What separates them is regulatory status, indication, and evidence base rather than potency. Tesamorelin possesses human trial evidence for visceral fat reduction in its approved patient population. In contrast, compounds such as sermorelin or CJC-1295 exhibit different pharmacokinetic half-lives and completely different regulatory profiles.

Is tesamorelin better than sermorelin?

The two peptides differ fundamentally in regulatory status and trial evidence. It holds an active prescription approval as EGRIFTA SV with phase 3 trial evidence confirming visceral fat reduction in patients with lipodystrophy. Sermorelin has no active commercial approval, exists only as a compounded drug, and lacks adult efficacy trials for body composition. However, tesamorelin is not approved for general weight loss, so neither compound can be considered better for off-label aesthetic purposes.

Is sermorelin the same as tesamorelin?

Sermorelin is not the same as tesamorelin. Sermorelin is a 29-amino-acid synthetic analogue of growth hormone-releasing hormone. Tesamorelin consists of a 44-amino-acid chain carrying a hexenoyl moiety attached to the N-terminal tyrosine. Furthermore, tesamorelin is an approved commercial drug, while all adult sermorelin sold in the United States is compounded.

Does tesamorelin cause diabetes?

Tesamorelin increases the risk of diabetes mellitus. In the pooled 26-week phase 3 clinical trials, the hazard ratio for developing diabetes was 3.3 compared to placebo, with a 95 percent confidence interval ranging from 1.4 to 9.6.

What happens when you stop taking tesamorelin?

Clinical trials demonstrate that abdominal visceral fat returns rapidly once tesamorelin injections are discontinued. In the 26-week treatment extension phases, patients switched from tesamorelin to placebo regained 16 to 22 percent of their visceral adipose tissue by week 52. The visceral fat gain returns when the drug stops.

Related